Patrick Daly

DocwireNews

According to Claire N. Harrison, MD, and colleagues, the addition of navitoclax to ruxolitinib improved treatment response in patients with myelofibrosis. Their study was motivated by preclinical models, which showed BCL-XL pathway inhibition was able to overcome resistance to Janus kinase inhibitor therapy.The trial, published in the Journal of Clinical Oncology, enrolled 34 patients with intermediate- to high-risk myelofibrosis who had progression or suboptimal response with ruxolitinib treatment (&ge;10 mg twice daily). Navitoclax was administered at a starting dose of 50 mg once daily. If platelet counts were &ge;75 &times; 109/L, the daily dose was escalated each week to a maximum of 300 mg.The primary outcome was &ge;35% spleen volume reduction (SVR35) at week 24 compared with baseline. Additional outcomes included &ge;50% total symptom score reduction (TSS50), hemoglobin improvement, safety, and change in bone marrow fibrosis grade.Researchers observed 58% of patients had high molecular risk mutations, and 52% had 3 or more mutations. Notably, 26.5% of patients at week 24 and 41% at any time achieved SVR35 with the navitoclax and ruxolitinib combination. The median overall survival was not reached over a median follow-up of 21.6 months.Additionally, 30% of patients achieved TSS50 at week 24, and bone marrow fibrosis was improved by 1 to 2 grades in 33% of evaluable patients. Anemia response was achieved by 64% of patients, including one with transfusion dependence at enrollment, the authors noted. For safety, the most common adverse event was reversible thrombocytopenia with no major bleeding events (88%).Ultimately, the authors found that adding navitoclax to patients on ruxolitinib therapy was promisingly effective and durable&mdash;particularly for this population with limited treatment options and difficult-to-manage disease.View More Recent <a href="https://www.docwirenews.com/latest-hematology-oncology-news-2/">Research and Expert Interviews in Hematology and Oncology</a>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Navitoclax Added to Ongoing Ruxolitinib for Myelofibrosis

Myelofibrosis

According to Claire N. Harrison, MD, and colleagues, the addition of navitoclax to ruxolitinib improved treatment response in patients with myelofibrosis. Their study was ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe